-
Mashup Score: 4JNCCN - 3 day(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer - 15 day(s) ago
Background: Hormone receptor (HR)–negative, HER2-positive (also called HER2-enriched) breast cancer has no worse prognosis than other breast cancers if it is treated with HER2-targeted therapy. Medicaid expansion under the Affordable Care Act (ACA) has been shown to be associated with improved access to care and outcomes for many cancers, but its association with receipt of care for HR-negative, HER2-positive breast cancer is unknown. We examined the association of Medicaid expansion with receipt of guideline-concordant treatment, time to treatment initiation, and survival among nonelderly women newly diagnosed with HR-negative, HER2-positive breast cancer. Patients and Methods: Women aged 18 to 62 years newly diagnosed with HR-negative, HER2-positive breast cancer between 2010 and 2018 were identified from the National Cancer Database. Outcomes included receipt of stage-based guideline-concordant treatment, timely initiation of treatment (<30 days, <60 days, <90 days from diagnosis),
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Association of #Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive #BreastCancer: https://t.co/khSFcYl4Dv @KSylvia_Shi @DrRobinYabroff @XuJi2022 @CharlesJiangMD @KathrynRuddyMD @SharonCastelli2 @HanXuesong #BCSM https://t.co/xhJnlFU7TU
-
-
Mashup Score: 0Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA) - 15 day(s) ago
Peripheral and deep en face margin assessment (PDEMA), formerly termed by NCCN as complete circumferential peripheral and deep margin assessment (CCPDMA), has the advantages of histologic visualization of the entire marginal surface, highly accurate resection of involved tissue, and sparing of uninvolved tissue. Owing to its highest reported cure rates, PDEMA is the NCCN-preferred treatment for dermatofibrosarcoma protuberans, high-risk basal cell carcinoma, and very-high-risk cutaneous squamous cell carcinoma. In the United States, Mohs micrographic surgery (Mohs) is the most common method of PDEMA. In Germany and some other countries, non-Mohs methods of PDEMA referred to as the Tubingen torte and muffin techniques are more widely used. The Tubingen methods of PDEMA require close communication between surgeon and pathologist. This article describes the background of both Mohs and Tubingen PDEMA, reviews what constitutes PDEMA, and provides a protocol for Tubingen PDEMA detailing crit
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Achieving Adherence With #NCCNGuidelines for Nonmelanoma #SkinCancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA): https://t.co/GvmpvzoPqJ #skcsm https://t.co/cRnI0PuLdK
-
-
Mashup Score: 4Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 29 day(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 5Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma - 29 day(s) ago
Older patients with multiple myeloma (MM) exhibit wide heterogeneity in their baseline physiologic and functional status, which demands an individualized treatment approach based on biological rather than chronological age. Various frailty scores have been developed for older patients with MM, but they are underutilized in clinical trials and in practice. Older patients with MM are underrepresented in therapeutic clinical trials, and treatment recommendations are currently derived from clinical trials of transplant-ineligible patients. This article provides a summary of phase II and III clinical trials in transplant-ineligible patients with newly diagnosed MM, highlighting outcomes in patients aged ≥75 years and frailty-based outcomes. The data available thus far show that triplet regimens are more efficacious than doublets in older patients but may be associated with higher toxicity. DRd (daratumumab/lenalidomide/dexamethasone) and VRd (bortezomib/lenalidomide/dexamethasone) are good
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With #MultipleMyeloma: https://t.co/60ohiHFooA #MMSM #gerinonc #hemeonc @siennadurbin @ryannipp @lundquistdebra https://t.co/UELVHB9g63
-
-
Mashup Score: 5Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma - 29 day(s) ago
Older patients with multiple myeloma (MM) exhibit wide heterogeneity in their baseline physiologic and functional status, which demands an individualized treatment approach based on biological rather than chronological age. Various frailty scores have been developed for older patients with MM, but they are underutilized in clinical trials and in practice. Older patients with MM are underrepresented in therapeutic clinical trials, and treatment recommendations are currently derived from clinical trials of transplant-ineligible patients. This article provides a summary of phase II and III clinical trials in transplant-ineligible patients with newly diagnosed MM, highlighting outcomes in patients aged ≥75 years and frailty-based outcomes. The data available thus far show that triplet regimens are more efficacious than doublets in older patients but may be associated with higher toxicity. DRd (daratumumab/lenalidomide/dexamethasone) and VRd (bortezomib/lenalidomide/dexamethasone) are good
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With #MultipleMyeloma: https://t.co/60ohiHFooA #MMSM #gerinonc #hemeonc @siennadurbin @ryannipp @lundquistdebra https://t.co/UELVHB9g63
-
-
Mashup Score: 2Association of Intellectual and Developmental Disabilities With Worse Outcomes After Surgical Treatment of Cancer - 30 day(s) ago
Background: Patients with intellectual and developmental disabilities (IDD) face unique challenges resulting in disparities in their health care. We sought to define the effect that IDD had on achievement of a “textbook outcome” (TO) following a cancer operation among a nationally representative cohort of patients. Methods: Data on patients who underwent surgery for a malignant indication, including lung, breast, liver, biliary tract, pancreas, and colorectal, between 2014 and 2020 were extracted from the 100% Medicare Standard Analytical Files database. The association of IDD with TO (defined as the absence of postoperative complications, extended length of stay, 90-day readmission, and 90-day mortality), expenditures, and discharge status was assessed using multivariable logistic regression. Results: Among 500,472 Medicare beneficiaries, 4,326 (0.9%) with IDD had a cancer diagnosis (breast, n=481; lung, n=419; hepatobiliary, n=194; pancreas, n=145; colorectal, n=3,087). Although over
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Association of Intellectual and Developmental Disabilities With Worse Outcomes After Surgical Treatment of Cancer: https://t.co/lfyQLt5qzC #hsronc @timpawlik @vivanresende6 @OhioStateSurg @OSUWexMed https://t.co/79rM2N1R96
-
-
Mashup Score: 5JNCCN - 1 month(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA
-
-
Mashup Score: 0Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 1 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 0Evaluation of Socioeconomic and Racial/Ethnic Disparities in All-Cause Mortality in Adolescents and Young Adults With Cancer - 2 month(s) ago
Background: Adolescent and young adult (AYA) patients with cancer have historically been understudied. Few studies have examined survival disparities associated with racial/ethnic and socioeconomic status (SES) and do not account for the influence of insurance status and access to care. We evaluated the association of SES and race/ethnicity with overall mortality for AYA patients who were members of an integrated health system with relatively equal access to care. Methods: AYA patients diagnosed with the 15 most common cancer types during 2010 through 2018 at Kaiser Permanente Southern California were included. Neighborhood Deprivation Index (NDI) quartile (Q1: least deprived; Q4: most deprived) was used as a measure of SES. Mortality rate per 1,000 person-years was calculated for each racial/ethnic and NDI subgroup. Multivariable Cox model was used to estimate hazard ratios (HRs) for all-cause mortality adjusting for sex, age and stage at diagnosis, cancer type, race/ethnicity, and ND
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Evaluation of Socioeconomic and Racial/Ethnic #Disparities in All-Cause Mortality in Adolescents and Young Adults With Cancer: https://t.co/vwdE3bj9o4 #cancerdisparities #healthequity #hsronc #ayacsm https://t.co/L1qlchTUSY
-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA